1. Home
  2. Clinical Topics
  3. FDA approves new treatment for rare types of non-Hodgkin lymphoma
Clinical TopicsDrugs and DevicesWeb Exclusives
rare types non hodgkin lymphoma

FDA approves new treatment for rare types of non-Hodgkin lymphoma

Share

On August 8, the U.S. Food and Drug Administration (FDA) approved Poteligeo (mogamulizumab-kpkc) injection for IV use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. These are two rare, hard-to-treat types of non-Hodgkin lymphoma.

Read more via U.S. Food and Drug Administration.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts